医学
放射治疗
肿瘤科
放射基因组学
循环肿瘤DNA
液体活检
精密医学
微小残留病
个性化医疗
内科学
疾病
前列腺癌
放化疗
癌症
病理
生物信息学
放射科
白血病
生物
无线电技术
作者
Noah Earland,Kevin Chen,Nicholas P. Semenkovich,Pradeep S. Chauhan,José P. Zevallos,Aadel A. Chaudhuri
标识
DOI:10.1016/j.semradonc.2023.03.004
摘要
Recent breakthroughs in circulating tumor DNA (ctDNA) technologies present a compelling opportunity to combine this emerging liquid biopsy approach with the field of radiogenomics, the study of how tumor genomics correlate with radiotherapy response and radiotoxicity. Canonically, ctDNA levels reflect metastatic tumor burden, although newer ultrasensitive technologies can be used after curative-intent radiotherapy of localized disease to assess ctDNA for minimal residual disease (MRD) detection or for post-treatment surveillance. Furthermore, several studies have demonstrated the potential utility of ctDNA analysis across various cancer types managed with radiotherapy or chemoradiotherapy, including sarcoma and cancers of the head and neck, lung, colon, rectum, bladder, and prostate . Additionally, because peripheral blood mononuclear cells are routinely collected alongside ctDNA to filter out mutations associated with clonal hematopoiesis, these cells are also available for single nucleotide polymorphism analysis and could potentially be used to detect patients at high risk for radiotoxicity. Lastly, future ctDNA assays will be utilized to better assess locoregional MRD in order to more precisely guide adjuvant radiotherapy after surgery in cases of localized disease, and guide ablative radiotherapy in cases of oligometastatic disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI